UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrolling By Invitation
99 years or below
All
Phase 3
10 participants needed

Brief description of study

The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['Leukemia, Myeloid, Acute']
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 829461
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.